PAR PHARMACEUTICAL TERMINATES PARTNERSHIP WITH ADVANCIS PHARMACEUTICAL CORPORATION

Par Pharmaceutical Companies, Inc. (NYSE: PRX -- News) today announced that it has terminated its partnership agreement with Advancis Pharmaceutical Corporation. The decision to terminate the partnership follows the recent release of results from Advancis' Amoxicillin PULSYS Phase III clinical trials. In both clinical trials, the Amoxicillin PULSYS product failed to achieve the desired microbiological and clinical endpoints. In 2004, Par entered into the agreement with Advancis to develop and market a novel formulation of the antibiotic amoxicillin.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20785720&full=1)